Figure 3 | Scientific Reports

Figure 3

From: Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies

Figure 3

Serial measurements of antibodies against SARS-CoV-2. (A) Changes in SARS-CoV-2 antibody titers in 109 serum samples from 22 inpatients measured three or more times in a row were plotted. Group M samples (n = 44 from 12 patients) and Group S samples (n = 65 from 10 patients) were tested. (i) NT antibody, (ii) S-IgG, (iii) S-IgM, and (iv) N-IgG. Clinical characteristics including outcome and past medical history of the patients are shown in Supplementary Table S2. The red horizontal lines indicate the positive threshold of each assay: NT antibody, 5 titer; S-IgG, 50 U/ml; S-IgM, 1.0 COI U/ml; N-IgG, 1.4 COI U/ml. (B) Slope analysis of (i) NT antibody, (ii) S-IgG, (iii) S-IgM, and (iv) N-IgG from Group M and Group S. Bars represent the means. Time points are within the following range of days after symptom onset: T1, day 0–13; T2, day 14–27; T3, day 28–41; T4, day 42–55. Statistical significance is indicated as follows: ∗p < 0.05, ∗∗p < 0.01 (Kruskal–Wallis test).

Back to article page